HCT outcome:
HCT outcome endpoints are listed in Table-S1. Patients were followed up
for a median of 30 (0.3–108) months. Fourteen patients (5.0%) died
early due to RRT and other transplantation-related complications, while
267 patients had documented engraftment (median day of engraftment was
16 days (range: 10–43 days). Post-transplant hematopoietic chimerism
evaluated in all patients who were alive beyond day +28 post HCT (n=264)
showed complete chimerism (CC) in 239 (90.5%), and mixed chimerism (MC)
(3-97% recipient cells) in 25 (9.5%) on day +28 post HCT. Twenty-two
of the 264 evaluable patients (8.3%) rejected their graft with the
median time of rejection of 2 months (0.7-14.2 months). Hepatic SOS and
mucositis were documented in 54 (19.2%) and 146 patients (I-2.8%, II-
25.2%, III- 22.7% IV-1.06%) respectively. Seventy-two (25.6%)
patients developed acute GVHD while thirty-one (11%) had chronic GVHD.
Overall, 225 (80%) patients were alive at the last follow-up and the
median event-free survival (EFS) was 76.8%. Fifty-six patients died
before day +100 (D+100 TRM). The major causes of death were steroid
refractory GVHD (35.7%), sepsis (33.9%), and fungal infections
(12.5%), SOS (10.7%), and multi-organ failure (7.1%).